lobbying_activities: 1122753

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1122753	f954f602-f0db-4c71-82e1-e677617cbfc2	Q2	APOTEX CORP.	310973	APOTEX CORP.	2011	second_quarter	PHA	S. 27, the Preserve Access to Affordable Pharmaceuticals Act Amending Section 505(j) of the Food, Drug, and Comsetic Act, concerning the ability of generic pharmaceutical manufacturers to file counterclaims seeking the correction of incorrect information submitted to FDA's Orange Book by patent owners or holders of New Drug Applications Supreme Court consideration of Novo Nordisk A/S and Novo Nordisk Inc. vs Carco Pharmaceutical Laboratories Ltd and Sun Pharmaceuticals Industries, Ltd Prospective action on legislation establishing a generic drug user fee program Prospection action on legislation establishing a biosimilar user fee program S. 296, the Preserving Access to Life Saving Medications Act Establishment of a federal track and trace system for pharmaceuticals	Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,SENATE		240000	0	0	2011-07-19T14:32:49.823000-04:00